-
Emerging approaches to the treatment of ventilator-associated pneumonia
B Mourvillier1, L Berra & J Wiener-Kronish
Review: Clinical Trail Outcomes: Clinical Investigation
-
Emerging approaches to the treatment of ventilator-associated pneumonia
B Mourvillier1, L Berra & J Wiener-Kronish
Review: Clinical Trail Outcomes: Clinical Investigation
-
Emerging approaches to the treatment of ventilator-associated pneumonia
B Mourvillier1, L Berra & J Wiener-Kronish
Review: Clinical Trail Outcomes: Clinical Investigation
-
Emerging approaches to the treatment of ventilator-associated pneumonia
B Mourvillier1, L Berra & J Wiener-Kronish
Review: Clinical Trail Outcomes: Clinical Investigation
-
Emerging approaches to the treatment of ventilator-associated pneumonia
B Mourvillier1, L Berra & J Wiener-Kronish
Review: Clinical Trail Outcomes: Clinical Investigation
-
Emerging approaches to the treatment of ventilator-associated pneumonia
B Mourvillier1, L Berra & J Wiener-Kronish
Review: Clinical Trail Outcomes: Clinical Investigation
-
Emerging approaches to the treatment of ventilator-associated pneumonia
B Mourvillier1, L Berra & J Wiener-Kronish
Review: Clinical Trail Outcomes: Clinical Investigation
-
Emerging approaches to the treatment of ventilator-associated pneumonia
B Mourvillier1, L Berra & J Wiener-Kronish
Review: Clinical Trail Outcomes: Clinical Investigation
-
Antiprotozoals for human African trypanosomiasis: the heart of darkness at dawn
Christian Burri
Commentary: Clinical Investigation
-
Antiprotozoals for human African trypanosomiasis: the heart of darkness at dawn
Christian Burri
Commentary: Clinical Investigation
-
Antiprotozoals for human African trypanosomiasis: the heart of darkness at dawn
Christian Burri
Commentary: Clinical Investigation
-
Antiprotozoals for human African trypanosomiasis: the heart of darkness at dawn
Christian Burri
Commentary: Clinical Investigation
-
Antiprotozoals for human African trypanosomiasis: the heart of darkness at dawn
Christian Burri
Commentary: Clinical Investigation
-
Antiprotozoals for human African trypanosomiasis: the heart of darkness at dawn
Christian Burri
Commentary: Clinical Investigation
-
Antiprotozoals for human African trypanosomiasis: the heart of darkness at dawn
Christian Burri
Commentary: Clinical Investigation
-
Antiprotozoals for human African trypanosomiasis: the heart of darkness at dawn
Christian Burri
Commentary: Clinical Investigation
-
Ecallantide for the treatment of acute attacks of hereditary angioedema due to C1-inhibitor deficiency
Jonathan Bernstein, Joseph Biedenkapp
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ecallantide for the treatment of acute attacks of hereditary angioedema due to C1-inhibitor deficiency
Jonathan Bernstein, Joseph Biedenkapp
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ecallantide for the treatment of acute attacks of hereditary angioedema due to C1-inhibitor deficiency
Jonathan Bernstein, Joseph Biedenkapp
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ecallantide for the treatment of acute attacks of hereditary angioedema due to C1-inhibitor deficiency
Jonathan Bernstein, Joseph Biedenkapp
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ecallantide for the treatment of acute attacks of hereditary angioedema due to C1-inhibitor deficiency
Jonathan Bernstein, Joseph Biedenkapp
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ecallantide for the treatment of acute attacks of hereditary angioedema due to C1-inhibitor deficiency
Jonathan Bernstein, Joseph Biedenkapp
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ecallantide for the treatment of acute attacks of hereditary angioedema due to C1-inhibitor deficiency
Jonathan Bernstein, Joseph Biedenkapp
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ecallantide for the treatment of acute attacks of hereditary angioedema due to C1-inhibitor deficiency
Jonathan Bernstein, Joseph Biedenkapp
Review: Clinical Trail Outcomes: Clinical Investigation
-
Trial discontinuation: lessons for future trial design?
Veerle JAA Nuij, Colin J de Haar & C Janneke van der Woude
Clinical Trail Methodology: Clinical Investigation
-
Trial discontinuation: lessons for future trial design?
Veerle JAA Nuij, Colin J de Haar & C Janneke van der Woude
Clinical Trail Methodology: Clinical Investigation
-
Trial discontinuation: lessons for future trial design?
Veerle JAA Nuij, Colin J de Haar & C Janneke van der Woude
Clinical Trail Methodology: Clinical Investigation
-
Trial discontinuation: lessons for future trial design?
Veerle JAA Nuij, Colin J de Haar & C Janneke van der Woude
Clinical Trail Methodology: Clinical Investigation
-
Trial discontinuation: lessons for future trial design?
Veerle JAA Nuij, Colin J de Haar & C Janneke van der Woude
Clinical Trail Methodology: Clinical Investigation
-
Trial discontinuation: lessons for future trial design?
Veerle JAA Nuij, Colin J de Haar & C Janneke van der Woude
Clinical Trail Methodology: Clinical Investigation
-
Trial discontinuation: lessons for future trial design?
Veerle JAA Nuij, Colin J de Haar & C Janneke van der Woude
Clinical Trail Methodology: Clinical Investigation
-
Trial discontinuation: lessons for future trial design?
Veerle JAA Nuij, Colin J de Haar & C Janneke van der Woude
Clinical Trail Methodology: Clinical Investigation
-
The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence
Andrew J Weickhardt, D Ross Camidge
Review Article: Clinical Investigation
-
The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence
Andrew J Weickhardt, D Ross Camidge
Review Article: Clinical Investigation
-
The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence
Andrew J Weickhardt, D Ross Camidge
Review Article: Clinical Investigation
-
The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence
Andrew J Weickhardt, D Ross Camidge
Review Article: Clinical Investigation
-
The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence
Andrew J Weickhardt, D Ross Camidge
Review Article: Clinical Investigation
-
The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence
Andrew J Weickhardt, D Ross Camidge
Review Article: Clinical Investigation
-
The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence
Andrew J Weickhardt, D Ross Camidge
Review Article: Clinical Investigation
-
The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence
Andrew J Weickhardt, D Ross Camidge
Review Article: Clinical Investigation